VPIM
VERV

Vanguard Personalized Indexing Management’s Verve Therapeutics VERV Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,526
Closed -$103K – 2035
2025
Q1 		$103K Buy
22,526
+1,285
+6% +$8.61K ﹤0.01% 1609
2024
Q4 		$120K Buy
21,241
+216
+1% +$1.22K ﹤0.01% 1594
2024
Q3 		$102K Buy
+21,025
New +$122K ﹤0.01% 1614

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Personalized Indexing Management's VERV Position: Q2 2025 in Review

Vanguard Personalized Indexing Management sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 22,526 shares — an estimated $103K sold.

Vanguard Personalized Indexing Management first reported a position in VERV in Q3 2024 and held it in 3 quarters. The position peaked at $120K in Q4 2024. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Vanguard Personalized Indexing Management reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Vanguard Personalized Indexing Management sold 22,526 Verve Therapeutics shares in Q2 2025, an estimated $103K.
  • Vanguard Personalized Indexing Management first reported a position in Verve Therapeutics in Q3 2024 and held it in 3 quarters.
  • Vanguard Personalized Indexing Management's Verve Therapeutics position peaked at $120K in Q4 2024.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2025, filed 25 Jul 2025.